-

Dexcom Launches Inaugural Venture Capital Fund

Dexcom Ventures to identify and invest in transformational technologies to advance long-term growth

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the launch of Dexcom Ventures. The inaugural fund will seek to identify and invest in opportunities to supplement growth in the core business and advance the development of adjacent technologies for the future.

Dexcom Ventures will be led by Dexcom veteran Steve Pacelli and will be focused on investment opportunities in sensing technology, data analytics, remote patient monitoring and population health, broadening Dexcom’s commitment to advancing better outcomes in healthcare.

“Driven by core technologies that our teams have developed internally, Dexcom continues to achieve strong growth and expand our future markets,” said Kevin Sayer, chairman, president and CEO of Dexcom. “By establishing Dexcom Ventures, we believe we can advance innovative technologies that enable better health outcomes and complement our growth opportunity. I have full confidence in Steve and his team as they lead this exciting new effort.”

The fund will support independent initiatives in glucose sensing technologies and in adjacent fields of metabolic monitoring and marks the entrance into the venture capital space for parent company Dexcom.

“We strive to be value-add strategic investors by leveraging access to Dexcom’s unique industry expertise and technology leadership,” Pacelli said. “While we have matured as a company over the years, we still consider ourselves to be a ‘start-up’ of sorts. We feel well positioned to invest early and support our portfolio companies as they pioneer markets.’’

About Dexcom

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.

Contacts

INVESTOR RELATIONS CONTACT:
Sean Christensen
Director of Corporate Affairs and Head of Investor Relations
investor-relations@dexcom.com
(858) 200-0200

MEDIA CONTACT:
James McIntosh
(619) 884-2118

DexCom, Inc.

NASDAQ:DXCM

Release Summary
Dexcom Launches Inaugural Venture Capital Fund
Release Versions

Contacts

INVESTOR RELATIONS CONTACT:
Sean Christensen
Director of Corporate Affairs and Head of Investor Relations
investor-relations@dexcom.com
(858) 200-0200

MEDIA CONTACT:
James McIntosh
(619) 884-2118

More News From DexCom, Inc.

Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026

BARCELONA, Spain--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and share more details about future product features across its global portfolio at the upcoming 19th annual Advanced Technologies and Treatments for Diabetes Conference in Barcelona, March 11-14, 2026. “There is no better global stage than ATTD to showcase how we’re...

Dexcom Appoints Rick Osterloh to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Rick Osterloh to Board of Directors...

Dexcom Announces Upcoming Conference Presentation

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 47th Annual Raymond James Institutional Investors Conference on Monday, March 2, 2026. The live presentation is scheduled to begin at approximately 1:05 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. D...
Back to Newsroom